Brian Bowser

[Brian Bowser @Beternal626]

I vide coded https://t.co/5iigCdcEAd over nine months and layered frontier AI over the top I would really like the opensource Ai's to server instead of the API costs from the four frontier AI's so I hope what you are saying is true. I hope they get smart enough to do tha same job.

[Brian Bowser @Beternal626]

@AlexFinn I vibe coded https://t.co/d9OFGXsnhi, took nine months and millions of downloads but I did it. 1 guy and 4 AI's now law is accessible to every human in the US for 24.95 a month and easy to understand and I am really old. Hahahaha

[Massimo @Rainmaker1973]

Carpenter found a really interesting note from 1975 while he was working on this house.

[Brian Bowser @Beternal626]

@LucasSa56947288 Based on Mitch's position the rather bright light should be reflected in his glasses on the left. His companion has it on his right side soooooo... you know fake

[Brian Bowser @Beternal626]

@JackStr42679640 https://t.co/TlTeeERvnt for 24.95 you can just this stuff up yourself. Easy to do.

[Brian Bowser @Beternal626]

@deancain Is it to soon to say "Damn Dinosaurs!"

[Brian Bowser @Beternal626]

@ConnieKRO1 Angelina you ignorant slut.

[Brian Bowser @Beternal626]

@Dineshkjoshi007 Alright DiCaprio there was enough room for your skinny ass.

[Brian Bowser @Beternal626]

@golden_tribee The internet has never had kids.

[Brian Bowser @Beternal626]

@SqSehrish 13

[Brian Bowser @Beternal626]

@WilliamShatner Um, I thought they were the same person?

[Brian Bowser @Beternal626]

@keezafaith $1.00 and I would be fine.

[Brian Bowser @Beternal626]

@Sofia50020Sofia KHAN!!!!!

[Brian Bowser @Beternal626]

@TheTimeTraveler Michael? Is that you?

[Brian Bowser @Beternal626]

@NatureUnedited We taste like pork.

[Brian Bowser @Beternal626]

@end3of6days9 That's funny. Normal brother sister rivalry. Dad's whipped, mom's jealous of hot daughter, mom just loves her handsome little boy and dads quietly disappointed with his son. Good timeds.

[Brian Bowser @Beternal626]

@AbrisGains Awesome!!! Thanks.

[Brian Bowser @Beternal626]

@HassanKhadair Both same time... two different screens. Then smoke something and really fuck with your head. 😂

[Nicolas Hulscher, MPH @NicHulscher]

BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal

84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION.

Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995.

The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole.

Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability.

At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either:
No evidence of disease (32.8%)
Tumor regression (15.6%)
or Cancer stabilization (36.1%)

Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months.

Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments.

This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential.

With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required.

In the meantime, many cancer patients are exercising their right to try.

@twc_health @McCulloughFund @IIAR_Journals @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson